Table 1.

Demographic characteristics of the patients on presentation

CharacteristicPatients (n = 21)
Age (range), y56.8 ± 16.5 (25–88)*
Gender
 Male18/21 (85.7%)
 Female3/21 (14.3%)
Chronic medical illness
 Hypertension9/21 (42.9%)
 Diabetes5/21 (23.8%)
 CHD2/21 (9.5%)
 COPD1/21 (4.8%)
 Brain infarction1/21 (4.8%)
 Bronchiectasis1/21 (4.8%)
 Auricular fibrillation1/21 (4.8%)
 CKD1/21 (4.8%)
Exposure
 Exposure to Wuhan5/21 (23.8%)
 Exposure to patients6/21 (28.6%)
Symptoms
 Fever21/21 (100%)
 Cough14/21 (66.7%)
 Phlegm9/21 (42.9%)
 Fatigue6/21 (28.6%)
 Chest tightness6/21 (28.6%)
 Nausea4/21(19.0%)
 Rhinorrhea1/21 (4.8%)
 Chest pain1/21 (4.8%)
Body temperature, °C38.8 ± 0.6 (37.6–40.6)
 37.6–38.611/21 (52.4%)
 38.6–39.68/21 (38.1%)
 39.6–40.62/21 (9.5%)
Time to progression, d5.6 ± 2.8 (2–14)*
Laboratory tests before tocilizumab
 Neutrophils percentage (%, 40–75)82.28 ± 9.14 (16/20, 80.0%)*
 Platelet count (×109/L, 125–350)170.35 ± 58.26 (4/20, 20.0%)*
 Erythrocyte sedimentation rate (mm/h, 0–15)42.42 ± 27.82 (10/12, 83.3%)*
d-dimer (μg/mL, 0–1.10)0.80 ± 0.92 (2/19, 10.5%)*
 Prothrombin time (s, 10.5–14.5)12.39 ± 2.12 (4/19, 21.1%)*
 Alanine aminotransferase (IU/L, 0–50)29.55 ± 14.44 (1/20, 5.0%)*
 Aspartate aminotransferase (IU/L, 15–40)31.15 ± 9.25 (1/20, 5.0%)*
 Creatine kinase (IU/L, 50–310)162.41 ± 74.77 (1/19, 5.3%)*
 Lactate dehydrogenase (U/L, 120–250)370.70 ± 140.21 (17/20, 85.0%)*
 Creatinine (μmol/L, 35–115)78.20 ± 26.46 (2/20, 10.0%)*
 Blood urea nitrogen (mmol/L, 3.1–8.0)5.64 ± 2.75 (2/20, 10.0%)*
State of illness
 Severe17/21 (81.0%)
 Critical4/21 (19.0%)
Oxygen therapy
 High-flow oxygen9/20 (45.0%)
 Nasal cannula7/20 (35.0%)
 Invasive ventilation2/20 (10.0%)
 Noninvasive ventilation1/20 (5.0%)
 Mask oxygen1/20 (5.0%)
Tocilizumab adverse events0
Clinical outcome
 Discharge from hospital21/21 (100%)
Hospitalization days (range), d§15.1 ± 5.8 (10–31)*
 ≤1413/21 (61.9%)
 14–216/21 (28.6%)
 ≥212/21 (9.5%)
  • Data are n/N (%) unless specified otherwise. CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

  • * Plus–minus values are means ± SD.

  • Patients who have confirmed COVID-19.

  • Not all patients received all relevant laboratory tests.

  • § Hospitalization days after the treatment with tocilizumab.